Right to FDA-Approved Medicines Act

Bill Number: H.R. 4525
Origin Chamber: House
Congress: 119th Congress, Session 1
Policy Area: Health
Status: Introduced
Latest Action: 2025-07-17: Referred to the House Committee on Energy and Commerce.
Last Updated: 2026-07-10T08:06:42Z

AI-Generated Summary

Purpose of the Legislation

The Right to FDA-Approved Medicines Act aims to establish a clear legal right for individuals to access medicines approved by the Food and Drug Administration (FDA) without interference, and to protect health care providers' ability to prescribe, provide, or share information about these medicines. It seeks to prevent government actions that coerce or restrict such access.

Key Provisions

Definitions:
"FDA-approved medicine" refers to any drug approved by the FDA under the Federal Food, Drug, and Cosmetic Act or licensed under the Public Health Service Act (essentially, legally approved medications).
"Government" includes all federal, state, and local entities and officials.
"Health care provider" covers licensed individuals or entities (e.g., doctors, nurses, pharmacists) authorized by a state to prescribe these medicines.
"State" broadly includes the 50 states, D.C., Puerto Rico, territories, and local governments.

Permitted Services and Rights:
Individuals have a statutory right to obtain FDA-approved medicines free from coercion.
Health care providers have a right to prescribe, provide, or share information, referrals, and related services about these medicines.
Governments cannot impose limitations (e.g., bans, rules, or requirements) that target or hinder access to these medicines, providers, or facilities, unless proven by "clear and convincing evidence" (a high legal standard) to significantly improve access without less restrictive options.
This does not limit the FDA's authority to approve or enforce drug approvals.

Applicability and Preemption:
The Act overrides conflicting federal and state laws (statutory or otherwise) that restrict access, sales, use, or aiding in obtaining these medicines.
It applies immediately upon enactment and preempts (takes priority over) future federal laws unless they explicitly reference and exclude it.
Exceptions: It does not affect health insurance coverage, benefits under group plans, or federal health programs (e.g., Medicaid preventive services).
Violations can be raised as a defense in legal actions.

Rules of Construction:
Courts must interpret the Act broadly to support its goals.
It prohibits government interference with providers or patients.
Individuals enforcing restrictive laws are treated as government officials for liability purposes.

Enforcement:
The U.S. Attorney General can sue states or officials to invalidate violating restrictions.
Private lawsuits: Affected individuals, providers, or entities (including on behalf of patients or staff) can sue states or officials for violations.
Remedies include court orders to stop restrictions (injunctive relief), plus costs and attorney fees for winning plaintiffs (but not for defendants in non-frivolous cases).
Federal courts have jurisdiction without requiring exhaustion of other remedies (e.g., no need to try administrative appeals first).
States and officials lose immunity from suits (abrogating protections under the 10th and 11th Amendments).

Severability: If any part is ruled unconstitutional, the rest remains in effect.

Significant Changes to Existing Law

Introduces new statutory rights to access and provide FDA-approved medicines, which did not previously exist at the federal level in this comprehensive form.
Broadly preempts state and federal restrictions on these medicines, overriding laws that single them out (e.g., targeted bans), even if adopted before or after the Act.
Overrides the Religious Freedom Restoration Act (RFRA), which allows religious exemptions from federal laws, preventing its use to justify restrictions.
Creates a private right of action against states and officials, waiving sovereign immunity (states' usual protection from lawsuits), and allows suits without prior administrative steps.
Shifts the burden in defenses to a high evidentiary standard ("clear and convincing") for any restrictions.

Potential Impacts

On Citizens: Enhances access to FDA-approved medicines by blocking government-imposed barriers, potentially making it easier for patients to obtain prescriptions without fear of state-level prohibitions.
On Health Care Providers: Protects their professional autonomy to prescribe and inform without legal repercussions from restrictive laws, reducing risks for providers and their staff.
On Government Agencies: Limits federal, state, and local governments' ability to enact or enforce targeted restrictions on specific medicines; the Department of Justice (via Attorney General) gains enforcement tools, while agencies like the FDA retain their approval powers unchanged. No direct impacts on international relations are outlined.
Broader Effects: Could lead to more uniform national access to approved drugs, but may increase litigation as states challenge or defend their laws.

Main Stakeholders Affected

Individuals and Patients: Gain protected rights to seek and use FDA-approved medicines.
Health Care Providers: Including doctors, nurses, pharmacists, and facilities, who can prescribe and provide information without undue restrictions.
Governments and Officials: Federal (e.g., Attorney General, FDA), state, and local entities face limits on regulatory powers and potential lawsuits.
Advocacy Groups and Entities: Organizations representing patients or providers may use enforcement mechanisms to challenge restrictions.

Notable Legal, Constitutional, or Political Implications

Legal: Establishes strong preemption, potentially invalidating state laws targeting specific FDA-approved drugs (e.g., those related to reproductive health or other controversial areas). The private right of action and fee-shifting provisions encourage lawsuits, while liberal judicial construction favors broad application.
Constitutional: Abrogates state sovereign immunity under the 10th and 11th Amendments, allowing federal and state court suits against states—unusual and likely to face challenges. Overrides RFRA, raising free exercise of religion concerns. Severability clause protects the Act's core if parts are struck down.
Political: Positions the federal government to intervene in state health regulations, promoting national standards for drug access but potentially sparking debates over federalism (balance of state vs. federal power) and specific policy areas like medication access. Neutral on partisan views, but could influence ongoing discussions on health care rights.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Ross, Deborah K. [D-NC-2]

Cosponsors (29)

Rep. Schrier, Kim [D-WA-8], Rep. Castor, Kathy [D-FL-14], Rep. Trahan, Lori [D-MA-3], Rep. Fletcher, Lizzie [D-TX-7], Rep. Watson Coleman, Bonnie [D-NJ-12], Rep. Williams, Nikema [D-GA-5], Rep. Cohen, Steve [D-TN-9], Rep. McClellan, Jennifer L. [D-VA-4], Rep. Strickland, Marilyn [D-WA-10], Rep. Clarke, Yvette D. [D-NY-9], Rep. Scanlon, Mary Gay [D-PA-5], Rep. DelBene, Suzan K. [D-WA-1], Rep. Escobar, Veronica [D-TX-16], Rep. Kennedy, Timothy M. [D-NY-26], Rep. Elfreth, Sarah [D-MD-3], Rep. Beatty, Joyce [D-OH-3], Rep. Meng, Grace [D-NY-6], Rep. Titus, Dina [D-NV-1], Rep. Peters, Scott H. [D-CA-50], Rep. Lieu, Ted [D-CA-36], Rep. Veasey, Marc A. [D-TX-33], Rep. Johnson, Julie [D-TX-32], Rep. Frankel, Lois [D-FL-22], Rep. Hayes, Jahana [D-CT-5], Rep. DeSaulnier, Mark [D-CA-10], Rep. McClain Delaney, April [D-MD-6], Rep. Craig, Angie [D-MN-2], Rep. Bell, Wesley [D-MO-1], Rep. Deluzio, Christopher R. [D-PA-17]

Recent Actions

2025-07-17: Referred to the House Committee on Energy and Commerce.
2025-07-17: Introduced in House
2025-07-17: Introduced in House

Bill Versions

Right to FDA-Approved Medicines Act — issued 2025-07-17 — PDF (10 pages)